antares
pharma
report
third
quarter
financial
operating
results
ewing
globe
newswire
antares
pharma
nasdaq
atrs
company
pharmaceutical
technology
company
today
announced
release
third
quarter
financial
operating
results
thursday
november
market
opens
antares
host
conference
call
thursday
november
et
discuss
results
numbers
domestic
callers
international
callers
conference
id
number
live
webcast
replay
conference
call
available
online
investor
relations
section
antares
pharma
corporate
website
antares
pharma
antares
pharma
pharmaceutical
technology
company
focused
primarily
development
commercialization
injectable
pharmaceutical
products
using
advanced
drug
delivery
auto
injector
technology
company
portfolio
proprietary
partnered
commercial
products
several
product
candidates
various
stages
development
well
significant
strategic
alliances
industry
leading
pharmaceutical
companies
including
teva
pharmaceutical
industries
teva
amag
pharmaceuticals
amag
pfizer
pfizer
idorsia
pharmaceuticals
idorsia
antares
pharma
products
include
testosterone
enanthate
injection
methotrexate
injection
subcutaneous
use
sumatriptan
injection
usp
distributed
teva
company
also
markets
desmopressin
acetate
licensed
ferring
pharmaceuticals
safe
harbor
statement
private
securities
litigation
reform
act
press
release
contains
statements
within
meaning
safe
harbor
provisions
private
securities
litigation
reform
act
statements
subject
certain
risks
uncertainties
cause
actual
results
differ
materially
described
factors
may
cause
differences
include
limited
company
ability
achieve
reinstated
revenue
guidance
uncertainty
regarding
duration
scope
severity
pandemic
mitigation
measures
restrictions
implemented
response
impact
demand
products
new
patients
prescriptions
future
revenue
product
supply
overall
business
operating
results
financial
condition
successful
commercialization
united
states
market
acceptance
future
revenue
adequate
reimbursement
coverage
commercial
success
future
revenue
market
acceptance
teva
generic
epinephrine
product
future
revenue
expectations
regarding
whether
fda
successful
pursuing
withdrawal
approval
amag
subcutaneous
auto
injector
following
recent
fda
advisory
committee
meeting
future
prescriptions
market
acceptance
revenue
teva
ability
successfully
commercialize
sumatriptan
injection
usp
amount
revenue
continued
growth
prescriptions
sales
successful
development
including
timing
results
clinical
bridging
phase
clinical
trial
drug
device
combination
product
selatogrel
idorsia
pharmaceuticals
fda
global
regulatory
approvals
future
revenue
fda
approval
teva
pending
anda
generic
forteo
future
revenue
timing
results
company
partners
research
projects
clinical
trials
product
candidates
development
actions
fda
regulatory
agencies
respect
company
products
product
candidates
partners
continued
growth
product
development
licensing
royalty
revenue
company
ability
meet
loan
extension
interest
payment
milestones
ability
repay
debt
obligation
hercules
capital
company
ability
obtain
financial
resources
research
development
clinical
commercial
activities
statements
regarding
matters
historical
facts
involve
predictions
statements
involve
known
unknown
risks
uncertainties
factors
may
cause
actual
results
performance
achievements
prospects
materially
different
future
results
performance
achievements
prospects
expressed
implied
statements
cases
identify
statements
terminology
may
would
expect
intend
plan
anticipate
believe
estimate
predict
potential
seem
seek
future
continue
appear
negative
terms
similar
expressions
although
statements
contain
identifying
words
additional
information
concerning
factors
may
cause
actual
results
differ
materially
anticipated
statements
contained
risk
factors
section
company
annual
report
form
company
periodic
reports
filings
securities
exchange
commission
company
cautions
investors
place
undue
reliance
statements
contained
press
release
statements
based
information
currently
available
company
date
hereof
company
undertakes
obligation
revise
update
statements
reflect
events
circumstances
date
press
release
except
required
law
contact
tram
bui
vice
president
corporate
communications
investor
relations
tbui
